While CTLA-4, PD-1, and PD-L1 are the primary focus of current ICIs, there are several other immune regulatory molecules that scientists are investigating as potential future targets for ICI therapies ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODIES for immune-mediated ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical ...

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...

Chinese biotech Akeso (HKEX: 9926) has reported encouraging early data from a Phase III trial of its bispecific antibody ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

Reports revenue $103,204 vs. $18.1M last year. “The clinical data we generated in 2024 with ADG126 gives us great confidence in our ability to ...